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ABSTRACT 
 
Human ABCG2 is a plasma membrane glycoprotein causing multidrug resistance in 
cancer. Membrane cholesterol and bile acids are efficient regulators of ABCG2 function while 
the molecular nature of the sterol-sensing sites has not been elucidated. The Cholesterol 
Recognition Amino acid Consensus (CRAC, L/V-(X)(1-5)-Y-(X)(1-5)-R/K) sequence is one of 
the conserved motifs involved in cholesterol binding in several proteins. We have identified 
five potential CRAC motifs in the transmembrane domain of the human ABCG2 protein. In 
order to define their roles in sterol sensing, the central tyrosines of these CRACs (Y413, 459, 
469, 570 and 645) were mutated to S or F, and the mutants were expressed both in insect and 
mammalian cells. We found that mutation in Y459 prevented protein expression; the Y469S 
and Y645S mutants lost their activity; while the Y570S, Y469F, and Y645F mutants retained 
function as well as cholesterol and bile acid sensitivity. We found that in the case of the Y413S 
mutant, drug transport was efficient, while modulation of the ATPase activity by cholesterol 
and bile acids was significantly altered. We suggest that the Y413 residue within a putative 
CRAC motif has a role in sterol-sensing and the ATPase / drug transport coupling in the 
ABCG2 multidrug transporter.  
 
Keywords: ABCG2, multidrug resistance, cholesterol, bile acids, cholesterol recognition 
amino acid consensus 
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1. Introduction 
 
ABCG2 is a plasma membrane glycoprotein in the ABC (ATP Binding Cassette) family of 
proteins that are characterized by a unique nucleotide binding/hydrolyzing domain (NBD) and 
hydrophobic membrane spanning sequences (transmembrane domain, TMD), mediating 
ATPase activity and the recognition and translocation of transported substrates, respectively. 
Several ABC transporters, called multidrug resistance (MDR) proteins, extrude various 
chemically unrelated compounds from the cells by utilizing the energy of ATP hydrolysis. 
ABCG2 is an MDR half transporter, harboring only a single NBD and a single TMD, and must 
at least homodimerize to exert its proper transporter function [1-3].  
ABCG2 is expressed in many tissues, most abundantly in organs displaying barrier 
functions (brain, placenta, and intestine) where it influences the passage of hydrophobic or 
slightly negatively charged molecules, including numerous drugs and food constituents. 
Therefore, ABCG2 can significantly influence the ADME-Tox (Absorption, Distribution, 
Metabolism, Excretion and Toxicity) properties of drugs, especially the absorption from the 
intestine, penetration to the central nervous system through the blood-brain-barrier, or the 
elimination from the liver or kidney [3-6]. Optimal activity of ABCG2 has been shown to be 
important in the regulation of serum urate levels, and polymorphic ABCG2 variants with 
decreased function or expression were shown to be associated with a higher risk of gout [7-9]. 
Human ABCG2 is expressed in stem cells of various origins, where it provides a protective role 
under hypoxic conditions [10]. Overexpression of ABCG2 confers multidrug resistance to 
cancer cells [11-13]. 
We and others have shown that both the ATPase and the transport activity of ABCG2 are 
significantly accelerated by cholesterol enrichment of “cholesterol poor” insect cell 
membranes; whereas cholesterol depletion of mammalian cells results in decreased ABCG2 
function [14, 15], implying that cholesterol is a major modulator of ABCG2 function. 
Subsequent studies have shown that functional reconstitution of purified ABCG2 requires 
cholesterol, suggesting that it is in fact essential for ABCG2 activity [16].  
The mechanisms by which cholesterol-ABCG2 interactions translate into the observed 
changes of function, or the site(s) involved in cholesterol sensing have not been defined. There 
is no experimental evidence proving direct binding of cholesterol by ABCG2 and it is not 
known if ABCG2 recognizes cholesterol as a transported substrate, as shown for some related 
ABCG transporters [17, 18]. More probably, cholesterol is an allosteric modulator of the 
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transporter, or may also have an indirect effect through influencing the biophysical properties 
of the lipid bilayer.  
Previous studies have suggested that single amino acids can influence cholesterol sensing 
of ABCG2. Mutation of R482 to small amino acids (D, G, N, S, T) were shown to alter the 
cholesterol sensitivity [19]; mutation of the leucines in the LxxL motif (potential steroid binding 
element (aa 555-558 [20]) resulted in an apparent cholesterol insensitivity of ABCG2 in Sf9 
membranes [19]. While these results may suggest that the mutated amino acids directly 
participate in cholesterol binding, they are not part of known motifs that characterize dedicated 
cholesterol binding regions. Many proteins that interact with cholesterol possess an amino acid 
consensus sequence termed “CRAC” (Cholesterol Recognition Amino acid Consensus) with 
the pattern (L/V-(X)(1-5)-Y-(X)(1-5)-R/K). The CRAC sequence was shown to be an essential 
determinant of cholesterol recognition in the peripheral-type benzodiazepine receptor, caveolin, 
the gp41protein of the HIV virus, or an integral outer mitochondrial membrane translocator 
protein [21-24]. The length of a CRAC motif varies between 5-13 amino acids, however, only 
the first and last amino acids and the central tyrosine residue are conserved. Various mutational 
studies of the CRAC motifs of cholesterol binding proteins and cholesterol-regulated ion 
channels have demonstrated the crucial role of the central tyrosine in cholesterol binding [22, 
23, 25]. 
Given the modulatory effects of cholesterol on ABCG2 activity, we screened the amino 
acid sequence of the protein for CRAC motifs. We have identified five putative CRAC 
sequences, and changed the central tyrosines to define each motif’s role in cholesterol-sensing. 
Here we show that the CRAC motif containing tyrosine at position 413 in transmembrane helix 
1, is involved in sterol sensing and the modulation of ATPase / transport coupling of the 
ABCG2 transporter. 
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2. Experimental procedures 
 
2.1. Materials - Cholesterol-RAMEB (Randomly Methylated -Cyclodextrin) was a kind 
gift from Cyclolab Hungary. All other chemicals were purchased from Sigma (Sigma Aldrich, 
Hungary) unless stated otherwise. 
2.2. Plasmid constructs - For the expression of ABCG2 mutants in insect cells, baculovirus 
plasmids containing the appropriate mutant ABCG2 cDNAs were generated by PCR 
mutagenesis, as described earlier [26]. The list of primers used for mutagenesis is provided in 
the “Supplementary material”. The PCR products were digested with PstI and NcoI enzymes 
and were ligated into the corresponding sites of the pAcUW21-L/wtABCG2 plasmid [27]. The 
base order of the constructs was confirmed by sequencing. The generation of the vector 
construct with the ABCG2-K86M mutant was described earlier [26]. 
The plasmids for stable expression in mammalian cell lines were created by the ligation of 
the appropriate fragments from pAcUW21-L/ABCG2-Tyr mutant between the NotI-BamHI 
sites of the pSB-CMV-wtABCG2 plasmid [28].  
2.3. Cells and cell lines - Sf9 cells (Invitrogen, Life technologies) were grown in TNM-FH 
insect cell medium complemented with 10 % FBS and 100 g/ml penicillin/100 U/ml 
streptomycin at 27oC. HEK 293 cells were cultured in D-MEM medium containing 10 % FBS 
and 100 g/ml penicillin/100 U/ml streptomycin and 5 mM glutamin at 37oC in 5% CO2. 
2.4. Generation of insect cells expressing ABCG2-Tyr mutants - Sf9 cells were co-
transfected with 250 ng linearized baculovirus DNA + 250 ng baculovirus plasmid DNA using 
the BaculoGold transfection kit following the protocol provided by the supplier (BD 
Biosciences). The presence of the engineered mutations was verified by restriction 
endonuclease digestion of the PCR-amplified ABCG2 DNA. 
2.5. Generation of HEK 293 cells stably overexpressing human ABCG2 and its Tyr 
mutants - Cells were transfected using 3 l Fugene6 reagent (Promega) and 500 ng of the 
Sleeping Beauty pSB-ABCG2 plasmid DNA and 500 ng plasmid coding a transposase [29]. 
48h post transfection the cells were cultured in 1 g/ml puromycin for 14 days. Cells 
overexpressing the highest amounts of the appropriate ABCG2 variant were sorted based on 
5D3 labeling using FACSAria cell sorter (Becton Dickinson). In cholesterol depletion 
experiments we used the HEK 293 cell line stably expressing the R482G mutant established 
earlier [15]. 
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2.6. Membrane preparation – Isolation of membranes from Sf9 cells expressing human 
ABCG2 or its Tyr mutants and the determination of membrane protein concentrations by the 
modified Lowry method were performed as described [30]. Besides control membranes 
prepared from untreated Sf9 cells, cholesterol pre-loaded membranes were also generated by 
co-incubation of the membranes with 0.25, 0.5, 1 or 2 mM cholesterol-RAMEB at 0oC for 30 
minutes prior to the final ultracentrifugation step of the membrane preparation procedure [15]. 
2.7. Detection of ABCG2 by Western blotting - Sf9 membranes or HEK 293 whole cells 
were suspended in sample loading buffer (62.5 M Tris HCl pH 6.8, 2 % SDS, 10 M EDTA-
Na pH 6.8, 10 % glycerol, 2M urea, 0.14 mg/ml bromophenol blue, 100 M dithiothreitol). 
Protein samples were separated on 7.5% Laemmli gels. Western blot analysis was performed 
as described earlier [26], by using the BXP-21 monoclonal antibody in a 2,000x dilution, and a 
goat anti-mouse HRP-conjugated secondary antibody (10,000x dilution, Jackson 
Immunoresearch). 
2.8. BXP-21 or 5D3 labeling - 5 x 105 HEK 293 cells were incubated in 1 ml HPMI buffer 
(120 mM NaCl, 5 mM KCl, 400 M MgCl2, 40 M CaCl2, 10 mM Hepes, 10 mM NaHCO3, 
10 mM glucose and 5 mM Na2HPO4 pH7.4), containing 0.5% bovine serum albumin and 1 
g/ml 5D3 antibody for 30 min at 37oC in the presence of 1 M Ko143. After washing, the 
cells were further incubated with a secondary, phycoerythrin-conjugated anti-mouse antibody 
(Molecular Probes, 2 g/ml). Fluorescence was analyzed in an Attune focusing flow cytometer 
(Applied Biosystems). 
When Sf9 membranes were labeled with anti-ABCG2 antibodies, 90 g membranes were 
incubated with BXP-21 (100x dilution) or 5D3 (final concentration 2 g/ml) antibody in a 
buffer containing 40 mM MOPS-Tris, 50 mM KCl and 500 M EGTA-Tris for 30 minutes at 
37oC, and after washing with phycoerythrin-conjugated goat anti-mouse antibody (final 
concentration 1 g/ml) for additional 30 minutes at 37oC. Fluorescence was analyzed in a 
FACSCalibur cytometer (BD Biosciences) [15, 31]. 
2.9. ATPase assay - Measurement of ATP hydrolysis was performed as described earlier 
[27]. The concentrations of test compounds used in the different experiments are indicated in 
the figure legends. Basal or drug-stimulated ATPase activities were compared to that measured 
in the absence of excess cholesterol. For the calculation of the KA values, the data were fitted 
with a non-linear dose response curve using the Origin 8.6 program. 
2.10. Vesicular uptake assay - The accumulation of 50 M 3H-methotrexate was measured 
for 10 minutes at 37oC, and the transport reaction was terminated by rapid filtration [32]. ATP-
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dependent transport was determined by subtracting the transport measured in the absence of 
MgATP from that of measured in the presence of 4 mM MgATP. 
2.11. Cellular uptake of Hoechst 33342, BODIPY-prazosin, Pheophorbide A and 
mitoxantrone – Accumulation of 1 M Hoechst 33342, 20 nM BODIPY-prazosin, 2 M 
Pheophorbide A or 5 M mitoxantrone was measured as described earlier [26]. Briefly, 5 x 105 
HEK 293 cells were co-incubated with the given compound at 37oC for 20 (Hoechst 33342 and 
BODIPY-prazosin) or 30 (Pheophorbide A and mitoxantrone) minutes. The reaction was 
terminated by the addition of ice-cold PBS. After centrifugation at 100 g for 5 minutes at 4oC, 
the cells were suspended in 1 ml PBS containing 1.25 g/ml propidium iodide and intracellular 
fluorescence was measured in an Attune (Hoechst 33342 and BODIPY-prazosin) or 
FACSCalibur (Pheophorbide A and mitoxantrone) cytometer. In the case of Hoechst 33342, 
cellular fluorescence “transport factor” was calculated as follows: (F100-F0)/F100*100, where F0 
is the fluorescence (mean values) of Hoechst 33342 in the absence of an inhibitor; F100 is the 
fluorescence (mean values) in the presence of 1 M Ko143.  
2.12. Cholesterol depletion - 1 x 106 HEK 293 cells were incubated with 0.9 ml 4 mM 
empty RAMEB diluted in HPMI for 30 minutes at 37oC. Then RAMEB was removed by 
centrifugation at 700 g for 5 minutes at room temperature, and the transport experiment was 
performed as described above. 
2.13. Determination of doxorubicin efflux - 5 x 105 HEK 293 cells were incubated with 
5 M doxorubicin in a final volume of 100 l for 30 minutes at 37oC in the presence or absence 
of 1 M Ko143. After washing the cells with 1 ml HPMI, the cells were further incubated in 
100 lHPMIwith or without 1 M Ko143 for 30 minutes at 37oC. The reaction was stopped 
by washing the cells with 1 ml ice-cold PBS. After centrifugation at 100 g for 5 minutes at 4oC, 
the cells were suspended in 1 ml PBS containing 1.25 g/ml propidium iodide and intracellular 
fluorescence was measured in an Attune flow cytometer at Ex/Em= 488 nm/574 nm.  
2.14. Cytotoxicity assay – 3 x 103 HEK 293 cells were seeded on flat bottom 96-well plates 
one day prior to the addition of the given drug. On day 0 drugs were pipetted onto the cells; at 
72h the supernatant was removed and 100 l 5% PrestoBlue (Life Technologies) was added to 
the cells. After incubation at 37oC, 5% CO2 for 1.5 hours, metabolized PrestoBlue was 
measured in a Perkin Elmer Victor X3 2030 Multilabel Plate Reader at 540 nm excitation and 
579 nm emission wavelengths. 
2.15. Statistical analysis of data – Statistical significance was assessed using paired 
Student’s t-test.  
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3.  Results 
 
3.1. Identification of potential CRAC motifs 
Cholesterol sensor motifs are located in or near the membrane plane; therefore we restricted 
our analysis to the transmembrane domain of ABCG2. We identified five putative CRAC motifs 
in ABCG2 (Fig. 1).  Alignment of the corresponding regions of the human ABCG proteins 
revealed that three out of the five identified CRAC motifs are also present in other members of 
the human ABCG family (see Figure 1, insert). The putative CRAC motifs identified in the 
sequence of human ABCG2 are also present in ABCG2 homologs. The 1st CRAC motif (aa 
407-418) is conserved amongst mammals (with the exception of rhesus monkey), but is absent 
in chicken, or lower species. The 2nd and 3rd potential CRAC motifs (aa 454-465 and 466-473, 
respectively) can be found even in various fish, e.g.  Atlantic salmon or Rainbow trout; the 4th 
and 5th putative CRAC motifs (aa 564-575 and 641-647, respectively) are conserved amongst 
vertebrates. 
 
3.2.  Expression and ATPase activity of ABCG2 CRAC mutants in Sf9 insect cells 
To analyze whether the putative CRAC motifs of ABCG2 influence cholesterol-sensing, 
we mutated the central tyrosines (Y413, 459, 469, 570 and 645) to Ser. The mutant proteins 
were expressed in Sf9 insect cells for functional measurements. All but one of the ABCG2 
mutants were successfully expressed in Sf9 insect cells. Mutation of Y459 to S prevented the 
expression of the protein, precluding this mutant from further analysis (Fig. 2A).  
Transport of substrates by ABCG2 is coupled to the hydrolysis of ATP. Measurement of 
the ATPase activity of the transporter is a well-established tool for the characterization of the 
activity of various mutant protein variants as well as for the screening of potential ABCG2-
interacting compounds [5]. In order to determine the functionality and the cholesterol 
dependence of the CRAC mutant ABCG2 proteins, we measured their ATP hydrolytic capacity 
in isolated Sf9 insect cell membranes. We found that mutation of Tyr to Ser at position 469 or 
645 resulted in the loss of ATP hydrolysis (even if the activity is corrected for the lower 
expression level of the Y469S mutant); while mutations in the other two positions apparently 
did not alter ABCG2 functionality, as both the Y413S and Y570S mutants showed a high level 
of ATPase activity, inhibited by a general ATPase inhibitor vanadate or the specific ABCG2 
inhibitor Ko143 (Fig. 2B).  
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In order to test if the inactivity of the Y469S and Y645S mutants was due to a specific loss 
of Tyr at this position, we also mutated these tyrosines to phenylalanines. We found that the 
Y469F and Y645F mutants were active (Fig. 2B), indicating the importance of the phenyl ring, 
but not of a hydroxyl group at these positions. 
 
3.3.  Effects of cholesterol on the ATPase activity of the CRAC mutants 
To test whether the CRAC tyrosine mutants are sensitive to the cholesterol content of the 
membranes, we characterized their ATPase activity in cholesterol-enriched insect cell 
membranes (Fig. 2C). The cholesterol content of the insect cell membranes is relatively low, as 
compared to mammalian cells (5-8 g cholesterol/mg membrane protein vs. 50 g 
cholesterol/mg membrane protein in insect and mammalian cells, respectively). Co-incubation 
with cholesterol-loaded cyclodextrin complexes was shown to be a reliable experimental tool 
to increase the cholesterol contents of Sf9 membranes by up to 10-fold [15]. Using this 
approach, we have shown that the ATPase activity, especially the activation of ATP hydrolysis 
by transported substrates, in the case of the wild-type ABCG2 is greatly enhanced when the Sf9 
membranes are enriched in cholesterol ( see [15] and Fig. 2C and Fig. 3A).  
We found that the basal ATPase activity of the Y469F, Y570S and Y645F mutants showed 
a moderate (approximately 20%, p<0.05) increase upon cholesterol addition, while the substrate 
stimulated ATP hydrolysis of the same mutants was significantly (50-100% increase, p<0.01) 
accelerated by cholesterol loading (Fig. 2C).  Therefore, these CRAC mutants behaved 
similarly to the wild-type ABCG2 protein. These results argue against a role of tyrosines 469, 
570 and 645 in cholesterol sensing, suggesting that the corresponding regions are not functional 
CRAC motifs.  
Conversely, we found that in the presence of cholesterol, the ATPase activity of ABCG2-
Y413S was distinct from that of the wild-type transporter. In the case of Y413S, cholesterol 
resulted in a major (50 +/- 8 %; p<0.01) enhancement of the basal ATP hydrolysis, which could 
be only slightly stimulated by the addition of prazosin or quercetin (Fig. 2B and C, and Fig. 
4B).  
Next, we investigated whether other compounds which are known substrates of wtABCG2 
also differently modify the Y413S-ATPase in the presence of cholesterol (Fig. 3). Again, 
cholesterol potentiated the drug-stimulated ATPase activity of the wild-type (Fig. 3A), as well 
as the 469F, the 570S and 645F mutants in the presence of several substrates (Supplementary 
Figure S1). In contrast, the Y413S mutant had a significantly altered ATPase modulation 
pattern. Quercetin showed a 30 +/- 6.5 %  stimulation (p<0.01), whereas doxorubicin, 
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flavopiridol, topotecan and SN-38 resulted in a concentration dependent inhibition (ranging 
from 26-70 %) of the ATPase activity of the protein (Fig. 3B, C, D and not shown).  
 For a detailed analysis of the effects of cholesterol loading, the basal and drug-
stimulated ATPase activities of the wild-type and Y413S ABCG2 mutants were compared at 
increasing membrane cholesterol concentrations. As shown in Fig. 4A, the baseline ATPase of 
Y413S is activated by lower cholesterol concentrations than that of the wild-type protein, with 
a lower apparent half-maximum cholesterol activation concentration (KA value of 0.37 +/- 0.27  
mM ) as compared to the apparent affinity of the wild-type protein (KA for cholesterol of 0.70 
+/- 0.09 mM). In contrast, in the case of the substrate-stimulated ATPase activities, wtABCG2 
showed higher sensitivity to cholesterol loading (Fig. 4B): in the presence of quercetin the 
calculated KA value for cholesterol activation of the wild-type protein was 0.22 +/- 0.20  mM, 
while, due to the low level of cholesterol activation a reliable KA for the Y413S protein could 
not be determined.  
 
3.4.  Altered bile acid sensitivity of the ABCG2-Y413S mutant  
The experiments described above showed that both the baseline ATPase activity and also 
the stimulation of the baseline ATP hydrolysis by various drugs of the Y413S mutant differ 
significantly from that of the wild-type protein when excess cholesterol is present. We have 
recently found that bile acids (steroids formed from cholesterol in the liver) significantly 
decrease the high basal ATPase activity of wtABCG2, while they do not interfere with the 
ABCG2-mediated ATP hydrolysis measured in the presence of substrates [16, 19]. This 
phenomenon results in a significant (up to 5-7 fold) increase in the relative, substrate stimulated 
ATP hydrolysis, depending on the type of bile acids.  In order to find out whether the active 
ABCG2 CRAC mutants have any alterations in their interactions with bile acids, we measured 
their ATPase activities in the presence of cholic acid, glycocholate and taurocholate.  
We found that the ATPase activities of the 570S, 469F, 645F and wild-type ABCG2 variants 
were similarly modified by bile acids (data not shown). In contrast, we found major differences 
in the effects of bile acids on the ATPase activity of the Y413S mutant. Though the addition of 
bile acids decreased the baseline ATPase activity of this ABCG2 mutant (Fig. 5A), bile acids 
also decreased ATP hydrolysis in the presence of substrates. Therefore the net result of bile 
acid effects was only a slight increase in the relative substrate stimulation of the Y413S mutant 
(Fig. 5B-D).  
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3.5.  Effects of cholesterol on the transport activity of the ABCG2 CRAC mutants in 
Sf9 membranes 
In addition to its effect on the ABCG2-ATPase activity, cholesterol has also been shown to 
significantly enhance the transport capacity of the protein – e.g. methotrexate transport by the 
wild-type ABCG2 was about 4-fold activated when the insect cell membrane vesicles were 
enriched in cholesterol [15]. To further analyze the consequence of the putative CRAC Tyr 
mutations on the cholesterol-sensing of ABCG2, we measured 3H-methotrexate transport both 
in control and cholesterol-loaded Sf9 membrane vesicles. As documented in Fig. 6, all the 
examined ABCG2 mutants, including Y413S, exhibited a methotrexate transport activity that, 
similarly to the wild-type transporter, was significantly (3-4 fold) enhanced by cholesterol 
loading of the membranes.  
 
3.6.  Expression and transport activity of ABCG2 CRAC mutants in HEK 293 cells – 
effect of cholesterol depletion  
According to the presented results the baseline ATPase activity of the ABCG2-Y413S 
mutant showed a sterol sensitivity that significantly differed from that of the wild-type, while 
in the vesicular transport measurement the effect of cholesterol on this mutant did not differ 
from that measured for wtABCG2. In order to further characterize the “cholesterol-
dependence” of the CRAC mutant ABCG2 proteins, we generated mammalian HEK 293 cells 
stably expressing the Y413S, Y469F, Y570S and Y645F mutants. Western blotting confirmed 
successful expression of these proteins (data not shown). Moreover, labeling with the anti-
ABCG2 5D3 antibody, which recognizes an extracellular epitope, indicated proper plasma 
membrane localization of these mutants (Supplementary Fig. S2).  
To characterize the effect of cholesterol on the ABCG2 transport function, we depleted the 
cholesterol content of the cells by co-incubation with cyclodextrin (RAMEB). This method 
decreases membrane cholesterol levels by about 25%, and was successfully used in earlier 
studies to define the effects of various cholesterol levels on ABCG2 function in mammalian 
cells [15, 33]. Previously we have demonstrated that mild cholesterol depletion of HEK 293 
cells resulted in a decreased transport function of wtABCG2, while did not alter the localization 
of ABCG2 or the viability of the cells [15].  
For measuring ABCG2 transport activity, intracellular accumulation of Hoechst 33342 was 
followed in control and cyclodextrin-treated HEK 293 cells, expressing the wild-type and the 
CRAC mutant ABCG2 variants. As shown in Fig. 7, all ABCG2 mutants, including Y413S, 
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were able to actively transport Hoechst 33342, and cholesterol depletion significantly decreased 
the Hoechst 33342 transport activity of all the CRAC mutants similarly to wild-type ABCG2.  
 
3.7. Putative CRAC mutants of ABCG2, including Y413S, effectively transport 
substrate drugs and protect HEK 293 cells against cytotoxic substrates 
The differential effects of the transported substrates on the wild-type and the Y413S 
ABCG2 ATPase activity may reflect different transport properties. Still, we did not find any 
alteration of the transport capacity or the cholesterol sensitivity of the Hoechst 33342 transport 
in the CRAC mutants.  
In order to further explore the relationship of altered drug-stimulated ATPase and transport 
activities, the transport of various fluorescent ABCG2 substrates was compared in HEK 293 
cells overexpressing wtABCG2 and the Y413S mutant, respectively.  No major difference was 
found in BODIPY-prazosin, Hoechst 33342, mitoxantrone and Pheophorbide A transport by 
any of the active mutants analyzed in this study (Table I). Interestingly, in spite of its different 
behavior in the ATPase assay, the Y413S mutant also did not differ significantly from the wild-
type protein, with respect to the transport of the above mentioned substrates.  
Among the cytotoxic drugs, the Y413S mutant ABCG2 protein (similarly to the wild-type) was 
able to transport doxorubicin (Fig. 8A) and provided protection against doxorubicin, SN-38, 
flavopiridol and topotecan, strongly indicating an active transport of these compounds by this 
mutant (Fig. 8B and Supplementary Fig. S3).  
  
CRAC motifs in ABCG2 
 13
 
 
4. Discussion  
 Understanding the regulation of the expression and function of ABCG2 may have 
important implications with regard to the modulation the ADME-Tox parameters of drugs and 
xenobiotics, in anti-cancer therapies, as well as in the treatment of gout. Cholesterol has been 
shown to be an essential activator of ABCG2 function [14-16], although the exact nature of the 
interaction between cholesterol and the transporter has not yet been defined. Also, the molecular 
determinants of cholesterol sensing by ABCG2 remain largely unknown [19, 20]. Cholesterol 
recognition amino acid consensus sequence (CRAC) motifs have previously been confirmed to 
be involved in cholesterol sensing of various proteins [21-25, 34, 35]. Site directed mutagenesis 
studies targeting conserved CRAC amino acids identified a large variety of protein-specific 
phenotypes. In the case of the HIV gp41 protein, CRAC mutations resulted in reduced 
cholesterol binding [35]; mutant peripheral-type benzodiazepine receptor variants showed 
altered cholesterol transport [34], while in ion channels the channel function was retained but 
regulation by cholesterol was abolished [25, 36].  
Here, we aimed to determine whether the CRAC motifs identified in the ABCG2 sequence 
play any role in the sterol sensing of the human ABCG2 multidrug transporter. We found five 
putative CRAC sequences located in or near the transmembrane helices of ABCG2 (Fig. 1). 
Based on the previous CRAC mutagenesis studies described above, we expected that mutation 
of a functional CRAC motif would modify the effect of cholesterol on ABCG2 function. We 
have approached this question by using a number of specific methods. 
ABC transporters couple ATPase and transport activities to promote the transmembrane 
movement of their substrates. This complex enzymatic activity can be followed in several 
experimental systems. ABCG2 expressed in Sf9 membranes displays relatively high baseline 
ATPase activity that can be moderately stimulated by transported compounds. The low intrinsic 
cholesterol content of the insect cell membrane allows the systematic modulation of membrane 
cholesterol levels. Using this model system, we and others have shown that the substrate-
stimulated ATPase activity of ABCG2 is significantly accelerated by cholesterol [14, 15]. 
Cholesterol makes up to 20% of the total lipids in mammalian cell membranes. Partial 
cholesterol depletion can be achieved by using “empty” cyclodextrins, which has been shown 
to result in a decrease of ABCG2 transport activity [15, 33]. Using this repertoire of assays we 
aimed to determine the role of the identified five CRAC motifs in the cholesterol-sensitive 
functions of ABCG2. 
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 We found that tyrosines of putative CRAC motifs predicted to be located in or near to the 
intracellular surface of ABCG2 (Fig. 1) are essential for protein expression and/or function. Tyr 
to Ser mutations at positions 459, 469 and 645 resulted in the loss of protein function, and the 
Tyr 459 to Ser mutation resulted in a complete loss of ABCG2 expression (Fig. 2). Insect cells 
are cultured at 27oC which has been shown to allow the expression of improperly folded 
proteins [37]. The fact that the Y459S mutant could not be expressed properly in insect cells 
suggests that the tyrosine at this amino acid position is crucial for the proper folding and 
processing of the protein and therefore might be an important determinant of ABCG2 structure. 
Recently, the Y459C heterozygous mutation was reported to occur in patients with renal cancer 
[38]. Therefore further exploration of the effect of mutations to residue 459 in ABCG2 is 
warranted.  
The Y469S and Y645S mutants could be expressed in comparable amounts to the wild-type 
protein, however, they were found to be non-functional (Fig. 2). These results may be 
interpreted in two ways. First, these tyrosines may be important for proper function or, 
alternatively, these mutants may lose their cholesterol sensing capability. Interestingly, 
introduction of a phenyl residue at the same position was found to be compatible with normal 
ATPase and transport activity, as well as with cholesterol sensing, indicating that these regions 
are not functional CRAC motifs. Rather, Y469 and Y645, along with Y459, may be important 
for proper folding of ABCG2. Our experiments, in which we tested the conformation of the 
ABCG2 mutants by labeling them with the conformation sensitive anti-ABCG2 5D3 antibody, 
revealed that the Y469S and Y645S mutants have decreased 5D3 binding capacity 
(Supplementary Figure S4). Therefore the loss of the activity of the Y469S and Y645S mutants 
is most probably due to their improper conformation and not by their altered cholesterol 
sensing.  
Previously, the Y645F mutation has been found to be functional, although has shown 
slightly decreased Hoechst 33342 transport capacity [39]. Interestingly, we did not find any 
major alteration in the substrate recognition by this mutant. Even its Hoechst 33342 transport 
capacity did not differ significantly from that of the wild-type protein (Fig. 7).   
The other two tyrosines (Y413 and Y570) mutated in this study are located in or near the 
extracellular surface of the transmembrane domain. We found that changing these amino acids 
is well tolerable for ABCG2, resulting in fully active proteins. The Tyr 570 to Ser mutation did 
not alter protein expression either in Sf9 or in HEK 293 cells, and substrate recognition and 
cholesterol-sensing of this mutant was also similar to that of the wild-type transporter (Fig. 2 
and 6 and Supplementary Fig. S1). 
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However, the Y413S mutant exhibited a distinct ATPase activity. This mutant showed a 
greatly increased baseline ATPase in the presence of low levels of added cholesterol (Fig. 4A), 
revealing an increased cholesterol sensitivity, while no further activation of the ABCG2-413S 
ATPase could be achieved by administration of transported substrates regardless of the 
cholesterol content of the membrane. Moreover, potential substrates that are known to activate 
the wild-type ABCG2-ATPase, rather inhibited the ATPase activity of the Y413S mutant (Fig. 
3). In addition to this altered cholesterol-sensing, the ATPase activity of the Y413S mutant also 
had an altered bile acid sensitivity, as this mutant was less sensitive to bile acids than the wild-
type protein (Fig. 5).  
The nature of the relatively high baseline ATPase activity of the human ABCG2 transporter is 
still not clarified. One explanation is an intrinsic, partially uncoupled function of the protein, 
manifesting in a “futile” ATP hydrolysis, keeping this multidrug transporter alert for rapid 
export of potentially harmful compounds [40]. Another possibility is the presence of an 
endogenous transported substrate, potentially cholesterol, triggering ATP hydrolysis without 
the addition of exogenous compounds. In the case of the Y413S mutant, cholesterol may 
promote “uncoupling” of the ATP hydrolysis in the ABCG2 protein. Alternatively, if we 
consider the possibility that cholesterol is transported by ABCG2, the results could be explained 
by a higher affinity to cholesterol by the ABCG2-Y413S mutant, also observed in the case of 
the R482G mutant [15]. The cholesterol-dependent increase in the ATPase activity is similar to 
that observed for several transported substrates. If ABCG2 can transport cholesterol, our data 
can be interpreted to suggest that the Y413S mutant is a more efficient cholesterol transporter. 
Unfortunately, experimental verification of cholesterol transport is difficult due to the lack of 
dedicated assays measuring ABCG2-mediated cholesterol transport. Tarling et al. [41] 
measured cholesterol efflux to HDL in ABCG1 and ABCG2 overexpressing cells, and found 
that, in contrast to ABCG1, ABCG2 is not able to transport cholesterol to HDL. Since ABCG2-
mediated cholesterol transport has not been experimentally confirmed, we speculate that the 
“cholesterol-stimulated” ATPase activity of the ABCG2-Y413S mutant is a result of its 
differential sensitivity to the modulatory effect of cholesterol.  
In contrast to these findings related to the ABCG2-ATPase activity, we did not find any 
significant alteration in the cholesterol sensitivity of the ABCG2-Y413S mediated transport 
either in insect cell vesicular transport, or mammalian whole cell transport assays. Active 
substrate transport by the Y413S mutant was clearly activated by cholesterol in both systems, 
and by all the compounds examined (Fig. 6 and 7). Moreover, the Y413S mutant protected the 
cells against toxic drugs similarly to the wild-type ABCG2. All these experimental data suggest 
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that although the ABCG2-Y413S mutant has an altered cholesterol interaction, it is rather 
manifested in a partial uncoupling of the ATPase activity of the transporter in the absence of 
transported substrates.   
      5. Conclusions 
Our study is the first detailed analysis of potential CRAC motifs within an ABC protein, 
and here we provide experimental data for various functional consequences of the mutations in 
these motifs in ABCG2. Surprisingly, none of the functional mutants, containing putative 
CRAC motifs analyzed here abolished the cholesterol-sensitivity of the transporter, although 
mutation of Y413 significantly affected cholesterol and bile acid interactions. These data 
suggest that Tyr 413 within a putative CRAC motif is most probably part of a sterol-dependent 
regulatory region of ABCG2 and may regulate the coupling of ATPase to transport activity.  
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FIGURE LEGENDS 
 
Figure 1. Topology model of human ABCG2 indicating the positions of tyrosines mutated 
in this study and also showing sequence alignment of human ABCG proteins. Protein 
sequences of human ABCG proteins (ABCG2 AAG52982.1, ABCG1 P45844.3, ABCG4 
NP_001135977.1, ABCG5 AG40003.1, ABCG8 AAG40004.1) were aligned using Clustalw 
(https://www.ebi.ac.uk/Tools/msa/clustalw2/). Putative CRAC motifs are underlined; the 3 
conserved amino acids in CRAC motifs are labeled with bold letters. The 2D structure was 
drawn by using http://emboss.bioinformatics.nl/cgi-bin/emboss/topo based on the topology 
created by CCTOP (http://htp.enzim.hu/?_=/viewer/HTP_002649) [42, 43].  
 
Figure 2. Expression and ATPase activity of ABCG2 CRAC tyrosine mutants in Sf9 insect 
cells. Panel A: Expression of CRAC mutants in Sf9 membranes. Sf9 membranes expressing 
wtABCG2 and its Tyr mutants were subjected to Laemmli gel electrophoresis. ABCG2 was 
visualized by the BXP-21 antibody. Panel B-C: ATPase activity of ABCG2-CRAC mutants 
in Sf9 insect membranes. Vanadate-sensitive ATPase activity was measured in non-treated 
(labeled as control, Panel B) insect membranes or in membranes loaded with 2 mM cholesterol-
RAMEB (Panel C) during the membrane preparation (see 2.6.) in the absence of added 
compounds (baseline), or in the presence of 1 M quercetin, 100 M prazosin or 1 M Ko143. 
Bars show the average of at least two independent experiments, each with two parallels, +/- 
S.D. values. 
 
Figure 3. Effect of known wtABCG2 substrates on the ATPase activity of wtABCG2 and 
the Y413S mutant. Vanadate-sensitive ATPase activity was determined in 2 mM cholesterol-
RAMEB treated membranes in the absence of substrates (baseline) or in the presence of 5 
quercetin doxorubicin, 20  SN-38, 50 flavopiridol or topotecan 
(Panels A and B). ATPase activity was also determined in the presence of increasing 
concentrations of doxorubicin or topotecan (Panels C and D). Figure shows the result of three 
independent experiments, +/- S.D. values. 
 
Figure 4. Effect of cholesterol on the wtABCG2 and Y413S-ATPase. Vanadate-sensitive 
ATPase activity was determined as described in 2.9. Control membranes were co-incubated 
with 0.25-2 mM cholesterol-RAMEB to achieve various membrane cholesterol levels. ATPase 
activity was measured in the absence of added substrates (Panel A) or in the presence of 5 M 
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quercetin (Panel B). The average of four independent experiments +/- S.D. values are shown. 
*: Student’s t-test, significant difference, p < 0.05. 
 
Figure 5: Effect of bile acids on the wtABCG2 and Y413S-ATPase. ATPase activity was 
determined in Sf9 membrane vesicles loaded with 2 mM cholesterol-RAMEB. Panel A: 
Vanadate-sensitive basal (no added substrate) or 1 M quercetin-stimulated ATPase activity in 
the absence or presence of 1 mM glycocholate (GC), 1 mM cholic acid (CA) or taurocholate 
(TC). Panel B: Relative ATPase activity in the presence of 1 M quercetin compared to the 
baseline is shown against increasing bile acid concentrations. Experiments were performed in 
quadruplicates, average +/- S.D. values are shown. 
 
Figure 6. Transport of 3H-methotrexate into control and cholesterol-loaded inside-out Sf9 
insect membrane vesicles. Intravesicular accumulation of 50 M 3H-methotrexate in Sf9 
membrane vesicles with different ABCG2 mutants containing 90 g of total membrane protein 
was measured at 37oC for 10 minutes in the presence or absence of 1 M Ko143. For the 
investigation of the effect of cholesterol, the membranes were loaded with 2 mM cholesterol-
RAMEB. Control represents non-loaded membranes. Bars represent average Ko143-dependent 
transport obtained in two independent experiments, each with two parallels  +/- S.D. values. 
 
Figure 7. Hoechst 33342 transport in ABCG2-expressing HEK 293 cells - effect of 
cholesterol depletion.  HEK 293 cells stably expressing wtABCG2 and its mutants were 
incubated with 2 M Hoechst 33342 for 20 minutes at 37oC with or without 1 M Ko143. After 
washing, cellular fluorescence of Hoechst 33342 was determined by flow cytometry. 
Cholesterol depletion was achieved by co-incubation of the membranes with empty 
cyclodextrin (see 2.12.); control values show results obtained with non-treated cells. Transport 
factor in living (propidium-iodide negative) cells was calculated as described in 2.11. 
Experiments were performed in quadruplicates; bars show the average of at least three 
independent measurements +/- S.D. values. 
 
Figure 8. Panel A: Doxorubicin efflux from HEK 293 cells. Doxorubicin (5 ) efflux was 
measured as described in 2.13.  Fluorescence of the cells was monitored by flow cytometry. 
Experiments were performed in duplicates. Figure shows representative graphs. Panel B. 
Cytotoxicy of ABCG2 substrates in HEK 293 cells. HEK 293 parental cells or stably 
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expressing wtABCG2 or its Y413S mutant were incubated with 50 nM SN-38, 50 nM topotecan 
(TOP), 60 nM doxorubicin (DOX) or 500 nM flavopiridol (FLP) for 72 hours. Cell viability 
was determined by PrestoBlue staining. 100% represents cells incubated at the same conditions 
in the absence of any drugs. Bars show the average of four independent experiments with 
quadruplicates each, +/- S.D. values. 
 
 
 
 
 
 








